White Guide and Orange Guide Formatting Project - Pfizer

Communicating Formulary Status
Mailing Clinical Studies to HCPs
Discussing Prior Authorizations
Orange Guide – Chapter 2: Detailing to HCPs
Q. Can I discuss with physicians the formulary status of Pfizer products as
compared with competitor products? If so, can I create a chart showing the
different formulary status by health plan?
A. In some circumstances, it might be appropriate to discuss the formulary status
of Pfizer and competitor products with HCPs provided that all statements you
make are accurate and do not make any non RC-approved direct or indirect
comparative claims. For example, you can point out when a Pfizer product has
a favorable formulary status, but you may not state or imply that the formulary
status makes the Pfizer product more effective or safer than a competitor
product. You are not permitted to create a formulary status chart because this
would be considered a homemade promotional piece, which is not allowed.
Q. What materials are available to me to help discuss formulary status?
A. The Corporate and Government Customers (CGC) group provides RC-approved
access grids (generated in the Fingertip Formulary System) which depict the
formulary status of Pfizer products. Contact the relevant CGC Account
Manager if information is not available in the Fingertip Formulary System or if
you need to request a copy of up-to-date formulary access grids.
Q. Am I permitted to mail an RC-approved clinical study (“reprint”) to an HCP?
A. Generally, no, unless there is explicit guidance and permission in iCUE to do so.
Q. Can I engage in discussions with HCPs about Prior Authorizations?
A. You should follow any applicable RC-approved guidance when engaging in a
discussion about specific prior authorization (PA) criteria or forms. In order for
you to give or show a specific PA form, it must be RC-approved or you must first
obtain written approval from an appropriate CGC representative. If a PA form
has been approved for distribution, you may discuss the relevant factual prior
authorization criteria with an HCP. If the form contains a Pfizer product name,
the applicable package insert must be left behind with any approved PA form.
You should never assist HCPs or staff in filling out any prior authorization form
and you may not coach anyone on fulfilling or evading a prior authorization
form’s requirements in order to obtain approval for either a specific patient or a
type of patient.
23
Rev. 09/12
Page 8 of 29